Does TOFACITINIB Cause Therapy cessation? 588 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 588 reports of Therapy cessation have been filed in association with TOFACITINIB (XELJANZ XR). This represents 0.4% of all adverse event reports for TOFACITINIB.
588
Reports of Therapy cessation with TOFACITINIB
0.4%
of all TOFACITINIB reports
3
Deaths
190
Hospitalizations
How Dangerous Is Therapy cessation From TOFACITINIB?
Of the 588 reports, 3 (0.5%) resulted in death, 190 (32.3%) required hospitalization, and 11 (1.9%) were considered life-threatening.
Is Therapy cessation Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TOFACITINIB. However, 588 reports have been filed with the FAERS database.
What Other Side Effects Does TOFACITINIB Cause?
Drug ineffective (30,382)
Pain (21,659)
Condition aggravated (16,925)
Arthralgia (15,640)
Fatigue (13,551)
Rheumatoid arthritis (12,277)
Off label use (11,736)
Headache (11,061)
Joint swelling (10,686)
Malaise (9,040)
What Other Drugs Cause Therapy cessation?
DALFAMPRIDINE (4,580)
ETANERCEPT (2,031)
ADALIMUMAB (1,712)
ABIRATERONE (1,602)
VOXELOTOR (1,038)
CLOZAPINE (885)
LOMITAPIDE (828)
CAPECITABINE (746)
TREPROSTINIL (743)
ISOTRETINOIN (633)
Which TOFACITINIB Alternatives Have Lower Therapy cessation Risk?
TOFACITINIB vs TOFERSEN
TOFACITINIB vs TOLNAFTATE
TOFACITINIB vs TOLODODEKIN ALFA
TOFACITINIB vs TOLTERODINE
TOFACITINIB vs TOLVAPTAN